Biotech

All Articles

Ideaya bags alternative on Biocytogen bispecific ADC in $400M bargain

.Ideaya Biosciences is actually wagering $400 thousand in biobucks that a bispecific antibody-drug c...

Takeda takes $140M loss on failed epilepsy drug, boasts FDA operate

.We actually recognize that Takeda is actually hoping to discover a pathway to the FDA for epilepsy ...

VBI Vaccinations files for personal bankruptcy, looks for asset purchase

.Immunology biotech VBI Vaccinations is actually drifting dangerously near to the climax, with plann...

Celldex anti-cKIT antibody decrease colonies in an additional stage 2 research study

.It's hard to muscular tissue in on a space as affordable as immunology, but Celldex Therapeutics fe...

Boehringer provides to $1.3 B for checkpoint inhibitor biotech

.Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapies and a preclinical immune sy...

Ventyx's last resort for inflammatory med ends in Crohn's failing

.Ventyx Biosciences' Crohn's disease medication did not assist clients accomplish remission in a sta...

Cognition's period 2 radiate information blemish Alzheimer's prospect

.Cognition Therapeutics' phase 2 SHINE trial has taken a few of the radiance off the Alzheimer's dis...

BMS axes bispecific months after submitting to function period 3 test

.Bristol Myers Squibb has actually had a whiplash change of heart on its BCMA bispecific T-cell enga...

Charles Baum manages Terremoto as CEO

.Charles Baum, M.D., Ph.D., that managed Mirati Rehabs' $ 5.8 billion sale to Bristol Myers Squibb i...

Asarina to shut after attempts to partner Tourette's medicine neglect

.After connecting to much more than 200 business to partner a Tourette syndrome treatment that revea...